CME Presentations

Food Allergy

Presentations

Speakers

  • Edwin Kim, MD, MS

    Edwin Kim, MD, MS

    Edwin Kim, MD, MS

    Associate Professor of Pediatrics

    Edwin Kim, MD, MS is an associate professor of pediatrics at the University of North Carolina (UNC) School of Medicine and chief of the division of pediatric allergy and immunology. He is director of the UNC Food Allergy Initiative research group, which focuses on multiple aspects of food immunotherapy including safety and tolerability of immunotherapy, varying levels of clinical desensitization, and immune mechanisms involved in successful treatment. Dr. Kim is also interested in research that focuses on the development of novel therapeutics for food allergy. As director, his goal is to recruit and train the next generation of leaders in allergy and immunology through strong clinical training and productive research opportunities.

    Session Appearances

    IgE-targeted Therapies and the Future Management of Food Allergies

  • Kristie Herring

    Kristie Herring

    Kristie Herring

    Caregiver

    Session Appearances

    IgE-targeted Therapies and the Future Management of Food Allergies

  • Ruchi Gupta, MD, MPH

    Ruchi Gupta, MD, MPH

    Ruchi Gupta, MD, MPH

    Professor of Pediatrics and Medicine

    Ruchi Gupta, MD, MPH is a professor of pediatrics and medicine at Northwestern University Feinberg School of Medicine and a clinical attending at the Ann & Robert H. Lurie Children’s Hospital of Chicago. With more than 20 years of experience as a board-certified pediatrician and health researcher, Dr. Gupta is the founding director of the Center for Food Allergy & Asthma Research (CFAAR). She is world-renowned for her groundbreaking research in the areas of food allergy and asthma epidemiology, most notably for her research on the prevalence of pediatric and adult food allergy in the United States. She has also significantly contributed to academic research in the areas of food-allergy prevention, socioeconomic disparities in care, and daily management of these conditions.

    Session Appearances

    IgE-targeted Therapies and the Future Management of Food Allergies

CME Information

Global LogoPQH Logo

IgE-targeted Therapies and the Future Management of Food Allergies

Jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC, in collaboration with the Asthma and Allergy Foundation of America (AAFA) and Food Allergy Research & Education (FARE).

ACKNOWLEDGEMENT

This activity is supported by an independent educational grant from Genentech, a member of the Roche Group.

DATE OF RELEASE/EXPIRATION

This activity was released on February 29, 2024 and is valid until March 1, 2025. Requests for credit must be made no later than March 1, 2025.

TARGET AUDIENCE

The primary target audience for this activity are Allergy/Immunology, Pediatrics (MD/DO/NP/PA). The secondary target audience are Primary Care providers (MD/DO/NP/PA).

STATEMENT OF NEED/PROGRAM OVERVIEW

The standard of care for people with food allergies continues to be strict allergen avoidance of offending foods and reactive management of symptoms with emergency medications. However, total allergen avoidance is challenging. There is a critical need for new approaches that improve outcomes for patients with food allergies. Immunoglobulin E (IgE) plays a critical role in the pathophysiology of food allergies and anti-IgE monoclonal antibodies are promising emerging therapeutic agents.

Join an expert panel of an allergist/immunologist and a primary care physician to discuss the diagnostic process for food allergies, the risks and benefits of current management options for patients and their caregivers, and the role of biologics for patients with and without comorbidities.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:
  • Clarify recommendations for the diagnosis and management of food allergies
  • Recognize the limitations and challenges faced by patients relying on allergen avoidance or using immunotherapy to manage food allergies
  • Summarize current evidence on the efficacy, safety, and place in therapy of emerging biologics that target the underlying IgE-driven pathophysiology of food allergies and common associated comorbidities
  • Discuss the place in care of agents targeting IgE and the role of shared decision-making in the management of people with food allergies

JOINT ACCREDITATION STATEMENT

JointlyAccreditedProvider Logo In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING EDUCATION

PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 45 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

FACULTY AND DISCLOSURE OF CONFLICTS OF INTEREST

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Name of Faculty or Presenter Conflicts of Interest
Edwin Kim, MD, MS
Associate Professor of Pediatrics
University of North Carolina School of Medicine
Dr. Edwin Kim, faculty for this educational activity, has the following relevant financial relationships:
• Consultant/Advisory Board/Speaker: ALK, Kenota Health, Ukko Inc, AllerGenis, Belhaven Biopharma, DBV Technologies, Genentech, Novartis, Nutricia, Revolo
• Safety Review Committee: Allergy Therapeutic Ltd
Ruchi Gupta, MD, MPH
Professor of Pediatrics & Medicine, Northwestern University Feinberg School of Medicine
Clinical Attending, Ann & Robert H. Lurie Children’s Hospital of Chicago
Director, Center for Food Allergy & Asthma Research (CFAAR)

Dr. Ruchi Gupta, faculty for this educational activity, has the following relevant financial relationships:
• Consultant/Advisory Board: Food Allergy Research & Support (FARE), Novartis, Genentech, Allergenis, Aimmune
• Researcher: National Institutes of Health (NIH), Food Allergy Research & Support (FARE), Novartis, Sunshine Charitable Foundation, Genentech.
Ownership Interest: Yobee Care, Inc.
Kristie C. Herring
Caregiver Panelist
Kristie C. Herring, a caregiver panelist for this activity, has no relevant financial relationships.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For additional information about the accreditation of this activity, please visit https://partnersed.com.

Technical Support:

For any technical issues or issues with your CME Certificate, please contact ImmunologyLive at 877-394-1306 or at Support@ImmunologyLive.com.